Recognition specifically addressed safety of Lallemand’s ProbioKid for use for infants, toddlers, and young children, based on safety and efficacy documentation reviewed by an expert panel.
In Canada, official recognition was extendedin March of this year to include infants over three months (you can check out ProbioKid’s product information in Health Canada’s Licensed Natural Health Products Database), with the health claim “helps to reinforce the body’s natural defenses in children.”
Included in the probiotic blend are Lactobacillus helveticus Rosell-52, Bifidobacterium infantis Rosell-33, and Bifidobacterium bifidum Rosell-71.
“Not only these achievements are key for the North American markets but they also can be seen as a global recognition of our strains safety in babies, being a vulnerable population,” said Solange Henoud, Regulatory Affairs Director.
According to marketing manager Bérengère Feuz, the recognition from North American authorities is validation of the product’s track record, “as it has been marketed for around 15 years around the world under various local brand names, with great market success stories like in China where it has been the best-selling probiotic formula for children since 2003.”
ProbioKid has been used in several pre-clinical and clinical studies, “showing its ability to help balance the immune response (Th1/Th2), to reduce the incidence of infectious episodes in children during winter, and to help support their immune response, probably by favouring immune maturity (Cazzola, 2010; Pantovic 2012),” according to a statement from the company.
“More recently, a study showed its effects in controlling the incidence of wheezing and respiratory infections in at-risk children during a 3- month intervention, with persisting effects for up to 9 months after the supplementation (Stojkovic et al. 2016).”